Filtered By:
Condition: Lupus
Drug: Hydroxychloroquine
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study
ConclusionCutaneous vasculitis and antiphospholipid antibodies (aPLs) are associated with an increased risk of ICVD, while HCQ therapy may provide protection against ICVD in SLE. The ICVD in younger lupus patients is associated with complement-mediated inflammation and poorer outcome, and require immunosuppressive therapy, whereas the ICVD in elderly patients are characterized by moderate ICAS and carotid atherosclerotic plaques.
Source: Frontiers in Immunology - September 27, 2022 Category: Allergy & Immunology Source Type: research

Recurrent cerebellar infarction associated with hereditary heterozygous protein C deficiency in a 35-year-old woman: A case report and genetic study on the pedigree.
In conclusion, the clinical manifestations of hereditary PROC deficiency may vary between individuals. The heterozygous mutation locus c.565C>T on the PROC gene is associated with thrombophilia. Awareness of the association between natural anticoagulants and thrombophilia may promote the prevention and therapy of stroke. PMID: 30210609 [PubMed]
Source: Experimental and Therapeutic Medicine - September 14, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study
ConclusionLong-term HCQ appears to have no vascular protective effect in patients with SLE.
Source: Rheumatology - September 27, 2017 Category: Rheumatology Source Type: research